A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study to confirm the selexipag starting dose(s), selected based on
pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults
doses in children from greater than or equal to (>=) 2 to less than (˂) 18 years of age with
Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active
metabolite ACT-333679 in this population.